Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia

Chest

Volumn 128, Issue 2, 2005, Pages 545-552

  Panidis, Dimitris ^a   Markantonis, Sophia L ^a   Boutzouka, Eleni ^b   Karatzas, Stylianos ^b   Baltopoulos, George ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b KAT HOSPITAL   (Greece)

Author keywords

Alveolar lining fluid; Bal; Gentamicin; Penetration; Ventilator associated pneumonia

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; GENTAMICIN; PIPERACILLIN PLUS TAZOBACTAM; TIMENTIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG LUNG LEVEL; DRUG PENETRATION; DRUG TISSUE LEVEL; FEMALE; FIBEROPTIC BRONCHOSCOPY; HUMAN; INTENSIVE CARE UNIT; LUNG ALVEOLUS; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 23744466563     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.2.545     Document Type: Article

References (41)

1. Richards MJ, Edwards JR, Culver DH, et al. Nosocomial infections in medical intensive care units in the United States: National Nosocomial Infections Surveillance System. Crit Care Med 1999; 27:887-892
2. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe: Results of the European Prevalence of Infection in Intensive Care (EPIC) Study; EPIC International Advisory Committee. JAMA 1995; 274:639-644
3. Chastre J, Fagon JY. Ventilator associated pneumonia. Am J Respir Crit Care Med 2002; 165:867-903
4. Bergogne-Berezin E. Pharmacokinetics of antibiotics in respiratory secretions. In: Pennigton JE, ed. Respiratory infections: diagnosis and management. New York, NY: Raven Press, 1988; 608-631
5. Baldwin DR, Honeybourne D, Wise R. Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance. Antimicrob Agents Chemother 1992; 36:1176-1180
6. Bergogne-Berezin E. Predicting the efficacy of antimicrobial agents in respiratory infections: is tissue concentration a valid measure? J Antimicrob Chemother 1995; 35:363-371
7. Valcke Y, Pauwels R, Van der Straeten M. Pharmacokinetics of antibiotics in the lungs. Eur Respir J 1990; 3:715-722
8. Drusano GL. Role of pharmacokinetics in the oucome of infections. Antimicrob Agents Chemother 1988; 32:289-297
9. Murray JF, Matthay MA, Luce JM, et al. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 1988; 138:720-723
10. The BAL Cooperative Group Steering Committee. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. Am Rev Respir Dis 1990; 141:S169-S202
11. Baldwin DR, Honeybourne D, Wise R. Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrob Agents Chemother 1992; 36:1171-1175
12. Rennard SI, Basset G, Lecossier D, et al. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 1986; 60:532-538
13. Taylor AE, Guyton AC, Bishop VS. Permeability of the alveolar membrane to solutes. Circ Res 1965; 16:353-362
14. Theodore J, Robin ED, Gaudio R, et al. Transalveolar transport of large polar solutes (sucrose, inulin, and dextran). Am J Physiol 1975; 229:989-996
15. Govantes C, Carcas AJ, Garcia-Satue JL, et al. Measurement of tobramycin in bronchoalveolar lavage fluid by a modified fluorescence polarization immunoassay. J Antimicrob Chemother 1995; 36:1111-1113
16. Carcas AJ, Garcia-Satue JL, Zapater P, et al. Tobramycin penetration into epithelial lining fluid of patients with pneumonia. Clin Pharmacol Ther 1999; 65:245-250
17. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13:818-829
18. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41
19. Lamer C, de Beco V, Soler P, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993; 37:281-286
20. Conte JE Jr, Golden JA, Kipps J, et al. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002; 46:1475-1480
21. Conte JE Jr, Golden J, Duncan S, et al. Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. Antimicrob Agents Chemother 1996; 40:1617-1622
22. Valcke YJ, Vogelaers DP, Colardyn FA, et al. Penetration of netilmicin in the lower respiratory tract after once-daily dosing. Chest 1992; 101:1028-1032
23. Braude AC, Hornstein A, Klein M, et al. Pulmonary disposition of tobramycin. Am Rev Respir Dis 1983; 127:563-565
24. Deziel-Evans LM, Murphy JE, Job ML. Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides. Clin Pharm 1986; 5:319-324
25. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155:93-99
26. Schentag JJ. Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentration, MIC values, and bacterial eradication in patients with Gram-negative pneumonia. Scand J Infect Dis Suppl 1990; 74:218-234
27. Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome Gram-negative pneumonia. Am J Med 1984; 77:657-662
28. Pennington JE. Penetration of antibiotics into respiratory secretions. Rev Infect Dis 1981; 3:67-73
29. Bodem CR, Lampton LM, Miller DP, et al. Endobronchial pH: relevance to aminoglycoside activity in Gram-negative bacillary pneumonia. Am Rev Respir Dis 1983; 127:39-41
30. Reynolds HY. Bronchoalveolar lavage: state of the art. Am Rev Respir Dis 1987; 135:250-263
31. Marcy TW, Merrill WW, Rankin JA, et al. Limitations of using urea to quantify epithelial lining fluid recovered by bronchoalveolar lavage. Am Rev Respir Dis 1987; 135:1276-1280
32. Fiscella RG, Gieser J, Phillpotts B, et al. Intraocular penetration of gentamicin after once-daily aminoglycoside dosing. Retina 1998; 18:339-342
33. Verbraeken H, Verstraete A, Van de Velde E, et al. Penetration of gentamicin and ofloxacin in human vitreous after systemic administration. Graefes Arch Clin Exp Ophthalmol 1996; 234(Suppl):S59-S65
34. Nau R, Scholz P, Sharifi S, et al. Netilmicin cerebrospinal fluid concentrations after an intravenous infusion of 400 ms in patients without meningeal inflammation. J Antimicrob Chemother 1993; 32:893-896
35. Bruckner O, Trautmann M, Kolodziejczyk D, et al. Netilmicin in human CSF after parenteral administration in patients with slightly and severely impaired blood CSF barrier. J Antimicrob Chemother 1983; 11:565-571
36. Celiloglu M, Celiker S, Guven H, et al. Gentamicin excretion and uptake from breast milk by nursing infants. Obstet Gynecol 1994; 84:263-265
37. Yoshioka H, Monma T, Matsuda S. Placental transfer of gentamicin. J Pediatr 1972; 80:121-123
38. Bernard B, Garcia-Cazares SJ, Ballard CA, et al. Tobramycin: maternal fetal pharmacology. Antimicrob Agents Chemother 1977; 11:688-694
39. Valcke Y, Pauwels R, Van der Straeten M. The penetration of aminoglycosides into the alveolar lining fluid of rats: the effect of airway inflammation. Am Rev Respir Dis 1990; 142:1099-1103
40. Mazzei T, Novelli A, De Lalla F, et al. Tissue penetration and pulmonary disposition of tobramycin. J Chemother 1995; 7:363-370
41. Kashuba AD, Nafziger AN, Drusano GL, et al. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by Gram-negative bacteria. Antimicrob Agents Chemother 1999; 43:623-629